ADVERTISEMENT
Updated
blue and white sign for the entrance to the FDA that says U.S. Department of Health and Human Services Food and Drug Administration
Biogen’s Alzheimer’s Drug Gets FDA Approval, Mixed Reviews
A lackluster performance in clinical trials of the monoclonal antibody aducanumab has left some experts unconvinced of its benefit.
Biogen’s Alzheimer’s Drug Gets FDA Approval, Mixed Reviews
Biogen’s Alzheimer’s Drug Gets FDA Approval, Mixed Reviews

A lackluster performance in clinical trials of the monoclonal antibody aducanumab has left some experts unconvinced of its benefit.

A lackluster performance in clinical trials of the monoclonal antibody aducanumab has left some experts unconvinced of its benefit.

immunotherapy, disease & medicine

A microscopy image of a mouse brain that shows the lymphatic system in bright purple and pink
Brain’s Lymphatic System Tied to Alzheimer’s Symptoms in Mice
Amanda Heidt | May 4, 2021 | 5 min read
A dysfunctional lymphatic system, described as a clogging of the brain’s sink, may explain why immunotherapies fail in some Alzheimer’s patients.
Bispecific Antibodies Treat Cancer in Mouse Models
Abby Olena, PhD | Mar 5, 2021 | 4 min read
A trio of papers shows that specialized antibodies can direct T cells to destroy cells that display portions of mutant cancer-related proteins, as well as T cells that have become cancerous themselves.
Contributors
The Scientist | Jul 13, 2020 | 3 min read
Meet some of the people featured in the July/August 2020 issue of The Scientist.
CAR T Cell Adds Scorpion Venom to Tackle Tumor Heterogeneity
Amy Schleunes | Mar 24, 2020 | 5 min read
A newly engineered CAR T cell that incorporates a peptide isolated from the venom of the deathstalker scorpion has broad brain tumor–binding capabilities that will be investigated in an upcoming clinical trial.
Novel DNA-Sensing Pathway Found in Human Cells, Absent in Mice
Catherine Offord | Jan 24, 2020 | 4 min read
This previously unknown mechanism for spotting foreign genetic material in the cytoplasm launches antiviral defenses even when the well-known immune mediator STING is absent.
car t chimeric antigen receptor t cell immunotherapy pyroptosis cell death perforin macrophage leukemia lymphoma
Side Effect of CAR T Therapy Caused by Pyroptosis: Mouse Study
Kerry Grens | Jan 20, 2020 | 2 min read
The immunotherapy induces a form of cell death in leukemia cells in mice that triggers cytokine release syndrome, a dangerous inflammatory reaction that occurs in some patients.
Immunology Leader Vincenzo Cerundolo Dies
Ashley Yeager | Jan 16, 2020 | 2 min read
The Oxford researcher’s work on lipid and peptide antigens revealed key mechanisms in inflammation, immunotherapy, and vaccination, which are being pursued in clinical trial treatments.
cardiac fibrosis car t chimeric antigen receptor immunotherapy t cells fibroblasts cardiovascular disease
CAR T Immunotherapy May Find New Use in Treating Cardiac Fibrosis
Emma Yasinski | Sep 11, 2019 | 3 min read
Scientists show the approach can kill cells that cause hardening of heart tissue in mice.
Chronic lymphocytic leukemia
T Cell Proliferation Linked to CAR T Responses
Ashley Yeager | Jul 15, 2019 | 2 min read
Comparing the cells of cancer patients who did and did not respond to the immunotherapy could reveal biomarkers to predict who should receive it in the first place.
Does the Microbiome Help the Body Fight Cancer?
Catherine Offord | Jul 10, 2019 | 4 min read
Research in mice and humans is beginning to establish a link between the composition of microbes in the gut and immune responses to tumor cells, but the mechanisms are not yet clear.
natural killer cells nk cell therapy product immunotherapy clinical trial
Clinical Trial Underway for a Natural Killer Cell Therapy
Chia-Yi Hou | May 7, 2019 | 3 min read
The cells, derived from induced pluripotent stem cells, are in testing as an immunotherapy for cancer patients with solid tumors.
peanut allergy anaphylaxis oit oral immunotherapy
Peanut Allergy Immunotherapy Increases Anaphylaxis Risk: Study
Kerry Grens | Apr 26, 2019 | 2 min read
Although the oral treatment seems to work, an analysis of the results from 12 clinical trials finds kids who got an immunotherapy have a greater rate of serious reactions.
t cell b cell lymphoma car t-cell therapy chimeric antigen receptor
A Revised CAR T for Lymphoma Has Fewer Side Effects
Kerry Grens | Apr 23, 2019 | 2 min read
An early-stage clinical study finds that none of the 25 patients treated developed neurotoxicity or cytokine release syndrome, common hazards of the cancer immunotherapy.
an illustration of T cells attacking a cancer cell
Two Patients Treated with CRISPRed Cells in Immunotherapy Trial
Shawna Williams | Apr 16, 2019 | 1 min read
One person with multiple myeloma and one with sarcoma are the first so far to receive the genetically engineered T cells in the study.
 immunotherapy  treatment may cause latent infections of Mycobacterium tuberculosis to flare up in cancer patients
Tuberculosis Can Emerge After Cancer Immunotherapy
Ashley Yeager | Apr 1, 2019 | 4 min read
At least a handful of patients have developed active TB after receiving cancer treatment designed to boost the immune system’s antitumor response.
Miriam Merad
Cancer Vaxxer: A Profile of Miriam Merad
Anna Azvolinsky | Apr 1, 2019 | 8 min read
The Mount Sinai oncologist studies innate immune cells with the goal of designing novel immunotherapies, including cancer vaccines.
april 2019 editorial the scientist
Miracle Elixirs
Bob Grant | Apr 1, 2019 | 3 min read
A long way into the quest to vanquish cancer, our ears strain to hear the words, “Cancer is cured”—a yearning that can cloud our judgment.
CAR Ts solid tumor
The Next Frontier of CAR T-Cell Therapy: Solid Tumors
Kerry Grens | Apr 1, 2019 | 10+ min read
The technology has wowed the field by all but obliterating some patients’ blood cancers, but solid malignancies present new challenges.
car t cell infographic april 2019 the scientist solid tumor liquid cancer
Infographic: CAR-T Cells in Solid Versus Liquid Cancers
Kerry Grens | Apr 1, 2019 | 2 min read
Tumor accessibility, heterogeneity, and microenvironment vary between the two classes of malignancies.
ADVERTISEMENT